No increase in aspiration or subsequent pneumonia seen among patients undergoing surgical procedures

Vaccination found to be safe and induces polyclonal immune responses against vaccine targets

Phase 3 trial shows 51 percent reduction in the risk for disease progression or death in triple-class exposed patients

Larger reductions seen in heart failure-related symptoms and physical limitations for patients with HFpEF, type 2 diabetes

In a recent study, the majority of patients were delabeled with no serious allergic reactions

Proportion of patient-reported qualifying conditions with substantial, conclusive evidence of therapeutic value decreased

Zevtera approved for S. aureus bloodstream infections, acute bacterial skin/skin structure infections, and bacterial pneumonia

Lower risk for clinically relevant bleeding seen in acute coronary syndrome, with no increase in risk for MACCE

Lower risks for first heart failure hospitalization, total heart failure hospitalization seen with empagliflozin

Fewer than half of cancer drugs granted accelerated approval demonstrate clinical benefit